Alkem Laboratories Limited Asset Resilience Ratio
Alkem Laboratories Limited asset resilience ratio. Alkem Laboratories Limited (ALKEM) has an Asset Resilience Ratio of 31.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Alkem Laboratories Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alkem Laboratories Limited (2011–2025)
Asset resilience ratio of Alkem Laboratories Limited from 2011 to 2025. This chart shows how Alkem Laboratories Limited's Asset Resilience Ratio has changed over time. See Alkem Laboratories Limited (ALKEM) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Alkem Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Alkem Laboratories Limited total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs15.48 Billion | 7.63% |
| Short-term Investments | Rs49.26 Billion | 24.28% |
| Total Liquid Assets | Rs64.74 Billion | 31.91% |
Asset Resilience Insights
- Very High Liquidity: Alkem Laboratories Limited maintains exceptional liquid asset reserves at 31.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alkem Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Alkem Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Alkem Laboratories Limited Asset Resilience Ratio by Year (2011–2025)
Alkem Laboratories Limited asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Alkem Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 24.32% | Rs43.03 Billion ≈ $465.35 Million |
Rs176.91 Billion ≈ $1.91 Billion |
-0.17pp |
| 2024-03-31 | 24.49% | Rs38.15 Billion ≈ $412.54 Million |
Rs155.75 Billion ≈ $1.68 Billion |
+4.62pp |
| 2023-03-31 | 19.88% | Rs27.34 Billion ≈ $295.71 Million |
Rs137.57 Billion ≈ $1.49 Billion |
+2.19pp |
| 2022-03-31 | 17.69% | Rs24.89 Billion ≈ $269.13 Million |
Rs140.69 Billion ≈ $1.52 Billion |
+3.89pp |
| 2021-03-31 | 13.79% | Rs15.89 Billion ≈ $171.85 Million |
Rs115.19 Billion ≈ $1.25 Billion |
+12.41pp |
| 2020-03-31 | 1.38% | Rs1.38 Billion ≈ $14.88 Million |
Rs99.46 Billion ≈ $1.08 Billion |
-2.62pp |
| 2019-03-31 | 4.01% | Rs3.29 Billion ≈ $35.58 Million |
Rs82.08 Billion ≈ $887.68 Million |
+1.66pp |
| 2018-03-31 | 2.34% | Rs1.80 Billion ≈ $19.44 Million |
Rs76.66 Billion ≈ $829.01 Million |
-6.61pp |
| 2017-03-31 | 8.95% | Rs5.88 Billion ≈ $63.59 Million |
Rs65.68 Billion ≈ $710.31 Million |
+3.10pp |
| 2016-03-31 | 5.85% | Rs3.24 Billion ≈ $35.02 Million |
Rs55.35 Billion ≈ $598.55 Million |
-7.98pp |
| 2015-03-31 | 13.83% | Rs7.33 Billion ≈ $79.23 Million |
Rs52.96 Billion ≈ $572.72 Million |
+7.38pp |
| 2014-03-31 | 6.46% | Rs2.81 Billion ≈ $30.36 Million |
Rs43.48 Billion ≈ $470.19 Million |
+4.79pp |
| 2013-03-31 | 1.66% | Rs673.10 Million ≈ $7.28 Million |
Rs40.48 Billion ≈ $437.80 Million |
-41.47pp |
| 2012-03-31 | 43.13% | Rs13.73 Billion ≈ $148.45 Million |
Rs31.82 Billion ≈ $344.16 Million |
+7.85pp |
| 2011-03-31 | 35.28% | Rs9.14 Billion ≈ $98.80 Million |
Rs25.89 Billion ≈ $280.03 Million |
-- |
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more